期刊文献+

他汀类药物对室性心律失常的作用及机制研究 被引量:1

Effects and Mechanisms of Statins on Ventricular Arrhythmias
下载PDF
导出
摘要 心脏性猝死是冠状动脉粥样硬化性心脏病患者的常见死因,而心脏性猝死大部分与致死性室性心律失常有关。大量研究表明他汀类药物可降低心血管疾病的发病率和病死率。令人注目的是大量的证据显示他汀类药物有抗室性心律失常的作用。他汀类药物可能通过增加副交感神经活性、改变跨膜离子通道的性质、修复粥样硬化斑块、稳定血小板、抗炎和抗增生作用、抗氧化作用、改善血管内皮功能、激活损害心肌、减轻因缺血导致的心肌细胞肥大等机制而有一定的抗室性心律失常的作用。 Sudden cardiac death is frequent among patients with coronary artery disease,and is related to life-threatening ventricular arrhythmias.Clinical and experimental evidence have demonstrated that therapeutic treatment using statins is significantly reduces cardiovascular morbidity and mortality.Compelling evidence from the majority of the studies reviewed shows that statins exhibit a protective effect against the occurrence of ventricular arrhythmias.The effects of statins against the occurrence of ventricular arrhythmias may be associated with mechanisms of decreasing parasympathetic tone,changing the properties of transmembrane ion channels,the regression of atherosclerotic plaques,stabilizing plaque,and many others.This review examines current research in the effects and mechanisms of treatments using statins on ventricular arrhythmias.
出处 《心血管病学进展》 CAS 2012年第3期331-334,共4页 Advances in Cardiovascular Diseases
关键词 他汀类药物 室性心律失常 作用 机制 statins ventricular arrhythmias effect mechanism
  • 相关文献

参考文献28

  • 1Zipes DP, Carnm J, Borggrefe M, et al. ACC/AHA/ESC guidelines for man- agcment of patients with ventficular arrhythmias and the prevention of sudden cardiac death : executive summary [ J ]. Circulation, 2006, 114 : 1088-1132.
  • 2Anne CP,Ebrahim B, Hajime U,et al. Pathogenesis of sudden unexpected death in a clinical trial of patients with myocardial infarction and left ventricular dys- function, heart failure, or both[J]. Circulation,2010,122:597-602.
  • 3Ozaydin M, Turker Y, Erdogan D,et al. Effect of previous statin use on the in- cidence of sustained ventricular tachycardia and ventricular fibrillation in pa- tients presenting with acute coronary syndrome [ J ]. Anadolu Kardiyol Derg, 2011,11(1) :22-28.
  • 4Wanahita N, Chen J, Bangalore S,et al. The effect of statin therapy on ventrie- ular tachyarrhythmias: 'a meta-analysis[ J]. Am J Ther, 2012,19 (1) :16-23.
  • 5Beri A, Contractor T, Khasnis A, et al. Statins and the reduction of sudden car- diac death: antiarrhythmic or anti-ischemic effect[J] ? Am J Cardiovasc Drugs, 2010,10(3) :155-164.
  • 6Das MK, Zipes DP,Rai SK,et al. Antiarrhythmic and nonantiarrhythmic drugs for sudden cardiac death prevention [ J ]. J Cardiovasc Pharmacol,2010,55 ( 5 ) : 438-449.
  • 7Beri A, Contractor T, Gardiner JC, et al. Reduction in the intensity rate of ap- propriate shocks for ventricular arrhythmias with statin therapy[J]. J Cardiovasc Pharmacol, 2010,56(2) :190-194.
  • 8Bloom HLI Shukrullah I, Veledar E,et al. Statins decrease oxidative stress and ICD theraoies[ J ]. Cardiol Res Pract, 2010,2010:253803.
  • 9Liu YB, Lee YT, Pak HN, et al. Effects of simvastatin on cardiac neural and electrophysiologic remodeling in rabbits with hypercholesterolemia [ J ]. Heart Rhythm, 2009,6( 1 ) :69-75.
  • 10Chen J, Nagasawa Y, Zhu BM, et al. Pravastatin prevents arrhythmias induced by coronary artery ischemia/reperfusion in anesthetized normocholesterolemic rats [ J ]. J Pharmaeol Sci,2003,93 : 87 -94.

同被引文献17

  • 1Chiu JH, Abdelhadi RH, Chung MK, et al. Effect of statin therapy on risk of ventricular arrhythmia among patients with coronary artery disease and an implantable cardioverter-defibrillator[J]. Am J Cardiol, 2005, 95(4):490-491. doi:10.1016/j.amjcard.2004.10.017.
  • 2Kaprielian R, Sah R, Nguyen T, et al. Myocardial infarction in rat eliminates regional heterogeneity of AP profiles, I(to) K(+) currents, and [Ca(2+)](1) transients[J]. Am J Physiol Heart Circ Physiol, 2002, 283(3): H 1157 -H 1168. doi: 10.1152/aj pheart.00518.2001.
  • 3Wickenden AD, Kaprielian R, You XM, et al. The thyroid hormone analog DITPA restores I(to) in rats after myocardial infarction[J]. Am J Physiol Heart Circ Physiol, 2000, 278(4):H1105-Hll16. doi: 10.1152/ajpbeart.O0244.2000.
  • 4Altrrmnn SW, Davis HJ, Zhu LJ, et al. Niemann-Pick C 1 Like 1 protein is critical for intestinal cholesterol absorption[J]. Science, 2004, 303(5661): 1201-1204. doi: 10.1126/science. 1093131.
  • 5Gagne C, Gaudet D, Bruckert E. Efficacy and safety of ezetimibe co- administered with atorvastatin or simvastatin in patients with homo- zygous familial hypercholesterolemia[J]. Circulation, 2002, 105(21): 2469-2475. doi:lO.1161/01 .CIR.0000018744.58460.62.
  • 6van der Graaf A, Cuffie-Jaekson C, Vissers MN, et al. Efficacy and safety of coadministration of ezetimibe and simvastatin in adolescents with heterozygous familial hypercholesterolemia[J]. J Am Coll Cardiol, 2008, 52(17):1421-1429. doi:10.1016/j.jacc.2008.09.002.
  • 7Kastelein JJ, Akdim F, Stroes ES, et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia[J]. N Engl J Med, 2008, 358 (14):1431-1443. doi: 10.1056/NEJMoa0800742.
  • 8Cannon CP, Giugliano RP, Blazing MA, et al. Rationale and design of IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimbe/simvastatin versus sim- vastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes[J]. Am Heart J, 2008, 156(5):826-832. doi: 10.1016/j .ahj .2008.07.023.
  • 9Blazing MA, Giugliano RP, Cannon CP, et al. Evaluating cardiovascular event reduction with ezetimibe as an adjunct to simvastatin in 18 144 patients after acute coronary syndromes: final baseline characteristics of the IMPROVE-IT study population[J]. Am Heart J, 2014, 168(2): 205-212. doi: 10.1016/j.ahj.2014.05.004.
  • 10Laufs U, La Fata V, Plutzky J, et al. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors[J]. Circulation, 1998, 97(12): 1129-1135. doi: 10.1161/01.CIR.97.12.1129.

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部